Claims
- 1. A method of treating depression, an obsessive compulsive disorder or anxiety in a human in need thereof which comprises administering an effective amount of N-acetyl-serotonin (NAS).
- 2. A method for the treatment of depression in a human being comprising the administration to said human being of an antidepressant amount of N-acetyl-serotonin (NAS).
- 3. The method of claim 2, wherein said NAS is administered by the oral route.
- 4. The method of claim 2, wherein said NAS is administered together with an acceptable carrier therefor.
- 5. The method of claim 2, wherein said NAS is administered in the form of an orally ingestible capsule or tablet.
- 6. The method of claim 2, wherein said NAS is administered in combination with a Ca.sup.++ antagonist.
- 7. The method of claim 6, wherein the Ca.sup.++ antagonist is nifedipine.
- 8. The method of claim 2, wherein said NAS is administered in combination with a selective serotonin uptake inhibitor or a inhibitor of monoamine oxidase.
- 9. The method of claim 8, wherein the selective serotonin uptake inhibitor is fluoxetine, flovoxamine, paroxetine or sertraline.
- 10. The method of claim 8, wherein the monoamine oxidase inhibitor is phenelzine, tranylcypromine, moclobemide, brofaromine or beflaxozone.
- 11. The method of claim 2, wherein said NAS is administered in combination with an inhibitor of NAS conversion into melatonin.
Parent Case Info
This application is a continuation of PCT/US98/06557, filed Apr. 1, 1998 and claims priorty to provisional application No. 60/043,049, filed Apr. 4, 19997.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4956361 |
Traber et al. |
Sep 1990 |
|
5552428 |
Fraschini et al. |
Sep 1996 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCTUS9806557 |
Apr 1998 |
|